NEW YORK (GenomeWeb News) — Investment bank Piper Jaffray cut its target price for shares in Invitrogen to $62 from $78 and downgraded its stock to “market perform” from “outperform” around two weeks after the company posted weak third-quarter financials.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.